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Introduction: Brugada syndrome (BrS) is an inherited arrhythmia syn-
drome with increased risk of syncope and sudden death. The typical ECG pat-
tern of ST-segment elevation in the right precordial leads can fluctuate.
Sodium channel blockers, such as ajmaline or flecainide, are used to unmask
the diagnostic ECG pattern of BrS in case of non-diagnostic basal ECG. There
is no direct comparison of the electrocardiographic modification induced by
these drugs in patients under the age of 15 years. The aim of this study is to
relate our experience in our reference centre.
Methods: Injections are performed by continuous infusion over a period of
10 minutes at 1mg/kg dose for ajmaline and 2 mg/kg for flecainide. Tests were
performed in case of absence of type 1 aspect on the resting ECG and in
absence of major conduction defects.
Results: The flecainide test (group F) was performed in 36 patients and
ajmaline test (group A) in 11 patients. Mean age was 12±4 years in group F
and 14±2 years in A (p=0.04). There was 14 girls in group F (39%) vs 4 in
group A (36%), NS. All patients were in sinus rhythm in both groups. There
was no difference between the two groups for heart rate 78±21 vs 72±15 bpm
(p=0.35), PR 148±28 ms vs 138±22 ms (p=0.32), QRS 87±11 ms vs 91+/-
10 ms (p=0.29) and QTc 412±40 vs 425±30 ms (p =0.31). During the test, HR
increase in both groups 9±12 vs 6±7 bpm (p=0.52). There was no difference
for PR 31±27 ms vs 32±22 ms (p=0.89). The QRS and QTc were slightly
higher in F group (QRS 25±23 ms vs 13±12 ms, p=0.11 and QTc 32±40 vs
18±15 ms, p=0.25) even if the difference was not significant. The number of
positive tests F 11/36 (31%) vs 3/11 (27%) were similar in both groups.
During pharmacological test no arrhythmic complications has been observed.
Conclusion: In patients under the age of 15 years and suspected of BrS,
the results of Flecainide and Ajmaline challenge are similar for conduction
parameters and positive results. The risk of ventricular arrhythmias appears
very low.
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Introduction: Brugada syndrome (BrS) is an inherited arrhythmia syn-
drome with an increased risk of syncope and sudden death. There is no report
of BrS in people aged 65 years old or more. The aim of this study is to
describe the clinical characteristics of BrS in elderly people.
Methods: BrS patients older than 65 years were recruited from 8 french
tertiary centers. Clinical data investigation of family history, 12-lead ECG and
results of pharmacological challenge were collected. Average follow-up was
78±48 months.
Results: 54 patients were recruited (mean age 69±4 years), 33/54 patients
(61%) were male. The circumstances of diagnoses were: systematic ECG
(n=23, 43%), symptoms (n=19, 35%) and familial screening (n=11, 20%).
25 patients (46%) were symptomatic: resuscitated sudden cardiac death (SCD)
in 1 patient (1.8%), 12 syncope (22%), 3 supraventricular tachycardia (6%),
6 palpitation (11%) and 9 lipothymia (17%). 15 patients have history of
familial SCD (28%). Implantable cardiac defibrillator (ICD) was implanted in
15/54 patients (28%) and 1 patient (1.8%) was implanted with pacemaker. At
baseline, mean HR was 68±14 bpm, PR 190±50 mm, QRS 105±16 mm and
QTc 422±43 mm. 29 patients (54%) have spontaneous type-1 ECG. Mean ST
elevation were 3.4±1.5 mm. During follow-up only 1/54 patients (1.8%) has
an arrhythmic event. This patient was symptomatic (syncope). 2 patients died
but their death was not due to a cardiac cause. We compared our results to the
patients aged under 65 years old of the FINGER BrS Registry (n=945
patients). The number of ICD implanted patients was higher in FINGER
cohort (28 vs 42%). Patients of the FINGER cohort presented more
arrhythmic events than patients aged 65 years or more in this study (5.2 vs
1.8%).
Conclusion: Patients aged more than 65 years old seem to represent a
lower-risk group than patients aged under 65 years old. Further studies are
needed in this population in order to identify risk factors in BrS patients aged
more than 65 years old.
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Introduction: Brugada syndrome (BrS) is an inherited arrhythmia syn-
drome with increased risk of syncope and sudden death. Disease manifestation
is clearly predominant in males and the studied population mainly consisted in
men. The aim of this study is to describe the clinical characteristics of BrS in
women.
Methods: BrS women were recruited from 12 french tertiary centers. Clin-
ical data, investigation of family history, 12-lead ECG and results for pharma-
cological challenge were collected. Average follow-up was 79±52 months.
Results: 202 women were recruited (mean age 46±16 years). Circum-
stances of diagnoses were: familial screening (n=94, 47%), systematic ECG
(n= 61, 30%) and symptoms (n=47, 23%). 69 patients (34%) were symptom-
atic: resuscitated sudden cardiac death (SCD) in 11 women (5%), 42 syncope
(21%), 8 supraventricular tachycardia (4%), 21 palpitations (10%), 24 lipo-
thymia (12%) and 7 pain (3%). 20 women (10%) have a history of familial
SCD. Implantable cardiac defibrillator (ICD) was implanted in 44/202 patients
(22%). At baseline, mean HR was 71±12 bpm, PR 174±32 mm, QRS
99±17 mm and QTc 419±29 mm. 59 women (29%) have a spontaneous type-
1 ECG. Mean ST elevation were 3.3±1.1 mm. During follow-up, 7/202
patients (3.5%) have an arrhythmic event: resuscitated SCD (n=1), syncope
(n=3), ventricular arrhythmia (n=1) and appropriate ICD shock (n=2). Among
them, 5 women were symptomatic (syncope) and 2 were asymptomatic.
Asymptomatic women don’t have a spontaneous type-1 ECG at baseline
whereas 3/5 symptomatic women have a type-1 ECG at baseline. We com-
pared our results to the men of the FINGER BrS Registry (n=745). The
number of ICD implanted patients was higher in FINGER cohort (22 vs 47%).
Men of the FINGER cohort presented more arrhythmic events than women of
this study (5.7 vs 3.5%).
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Conclusion: Women seem to represent a lower-risk group than men. A
spontaneous type-1 ECG at baseline doesn’t seem to be a risk factor for
arrhythmic event in women.
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Background: Rhythmic complications seem common after left ventricular
(LV) assist device (LVAD), especially in the early phase of implantation
(<30 days). We sought to identify the incidence and risk factors of arrhythmic
storm occuring after Heart Mate® 2 (HM2) implantation.
Methods: All patients with HM2 implanted in our institution have been
studied. Clinical data, occurrence of arrythmia, implantable cardioverter-defi-
brillator (ICD), ultrasound parameters as well as follow-up have been ana-
lyzed.
Results: From January 2008 to April 2013, 33 patients (30 men,
58±10 years, LVEF 20 ±5%, ischaemic cardiomyopathy 82%, 70% bridge to
transplant), were included. Before implantation, 15 had ICD (12 for primary
prévention) and 11 had a history of sustained ventricular tachycardia (VT).
The overall mortality rate was 48% with a mean follow-up of 11±11 months.
Post-LVAD arrhythmic storm (10 patients, including 9 in the first 30 days)
were more frequent in patients with prior VT (70% vs 17%, p<0.01), prior
ICD (80% vs 30%, p=0.01), larger LV end diastolic diameter (77±9 vs
67±6 mm, p=0.02) and non ischaemic cardiomyopathy (40 vs 8%, p=0.053).
Arrhythmic storm occuring just prior LVAD implantation (8 patients) was not
associated with arrhythmic storm recurrence after. Endocardial VT ablation
was performed in 6. The substrate was not related to HM2 cannula.
Conclusion: Arrhythmic storm are frequent (33%) after HM2 implantation,
often occurring within one month in patients with prior VT episode.
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Objectives: New-onset atrial fibrillation (NAF) is a common complication
of septic shock and incidence is underestimated. We sought to investigate the
real incidence, associated risk factors for NAF, and its prognostic impact
during septic shock in patients hospitalized in a medical Intensive Care Unit
(ICU).
Design: Prospective, single-center, observational study.
Setting: Medical ICU in a large university teaching hospital.
Patients: All consecutive patients presenting between March 2011 and
May 2013 with septic shock were eligible for inclusion, with the following
exclusion criteria: patients aged <18 years, prior history of AF (paroxysmal or
sustained), and patients transferred from another ICU with prior septic shock.
Intervention: After inclusion, all patients were equipped with long-dura-
tion Holter ECG monitoring for 7 days.
Measurements and Main Results: NAF was defined as an AF episode
lasting more than 30 seconds. Patient characteristics, infection criteria, cardio-
vascular parameters, severity of illness, medical and technical support thera-
pies were recorded. Among 66 patients, 29 (44%) developed NAF; 10 of
which (34%) would not have been diagnosed without Holter ECG monitoring.
NAF patients were older, and more often presented markers of heart failure,
i.e. higher troponin and NT-pro-BNP levels associated with lower left ventric-
ular ejection fraction (LVEF), as compared to patients who remained in sinus
rhythm. NAF patients also had longer QRS duration and more often presented
nonsustained supra ventricular arrhythmias (<30s) on the first day. In a multi-
variate model, only age (OR: 1.06; p=0.01) and LVEF<45% (OR: 13.01,
p=0.03) remained associated with the occurrence of NAF. However, NAF was
not an independent predictor of 28 or 90 day mortality.
Conclusion: This is the first study to examine the exact incidence and risk
factors of NAF in septic shock patients. NAF is common, especially in older
patients, and is associated with low ejection fraction. We did not find NAF to
be independently associated with higher mortality in this study.
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Objectives: The aims of our study were to assess silent AF incidence after
acute myocardial infarction (AMI) and determine its impact on patient’s out-
come.
Background: Silent AF has been suggested to be common in AMI. But its
true incidence and patient’s clinical outcome remain unknown.
Methods: 849 consecutive AMI were prospectively analyzed by contin-
uous ECG monitoring (CEM) during the first 48 hours after admission. Silent
AF was defined as asymptomatic episodes lasting at least 30 sec. The popula-
tion was studied into three groups: No AF, Silent AF, and symptomatic AF
after AMI.
Results: One hundred and thirty five patients (15.9%) developed silent AF.
Compared with the no AF group, patients with silent AF were markedly older
80 (67-85) vs. 62 (53-75) years; with p<0.001), more frequently women (58
(43%) vs. 198 (30%); with p=0.006), and less smoker (26 (20%) vs. 242
(36%); with p<0.001). They had a significant left atrial (LA) enlargement with
LA surface indexed 10.79 (8.61-12.58) vs. 9.30 (7.54-11.04)cm²/m²; with
p<0.001 and LA volume indexed 29.50 (21.30-44.05) vs. 24.45 (18.25-
33.15)cm3/m²; with p<0.001. Comparing these three groups, heart failure epi-
sodes after AMI were more frequent in silent AF group (36 (41.5%)) and in
symptomatic AF group (27 (60.0%)) than in no AF group (139 (20.8%)) with
p<0.001, and in-hospital mortality was higher in silent AF group (14 (10.4%))
and in symptomatic AF group (8 (17.8%)) than in no AF group (9 (1.3%))
with p<0.001. By multivariate analysis, silent and symptomatic AF, LVEF and
GRACE risk score were identified as independent explanatory variables for
occurrence of in-hospital death after AMI.
Conclusion: Silent AF is very common after AMI and impacts patient’s
outcome with more frequent episodes of heart failure (41.5%) and higher in-
hospital mortality (10.4%). Our large prospective study suggests that silent AF
screening should be improved after AMI in order to predict the prognosis of
patients.
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